A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Inclusion Criteria:

1. Previously untreated adult patient ≥ 18 years with a confirmed diagnosis of CLL.

2. CLL requiring treatment as per pre-defined criteria.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0,1, or 2.

4. Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI).

5. Adequate marrow function.

6. Adequate liver function as indicated by aspartate aminotransferase (AST) alanineaminotransferase (ALT) and serum total bilirubin.

7. Adequate renal function.

8. Life expectancy > 6 months.

9. Signed informed consent and able to comply with the study protocol in theinvestigator's judgment.

10. Women of childbearing potential must be willing to use a highly effective method ofbirth control for the duration of the study and for ≥ 90 days after the last dose ofstudy drug.

Exclusion Criteria:

1. Known prolymphocytic leukemia or history of, or currently suspected, Richter'stransformation

2. Known central nervous system involvement

3. Received previous systemic treatment for CLL

4. Clinically significant cardiovascular disease

5. Severe or debilitating pulmonary disease

6. History of prior malignancy

7. Active fungal, bacterial, and/or viral infection requiring systemic therapy

8. Positive human immunodeficiency virus (HIV) serology (HIVAb) status or serologicstatus reflecting active hepatitis B or C infection

9. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiringtreatment

10. History of severe bleeding disorder such as hemophilia A, hemophilia B, vonWillebrand disease, or history of spontaneous bleeding requiring blood transfusionor other medical intervention

11. History of stroke or intracranial hemorrhage ≤ 6 months before the first dose ofstudy treatment

12. Unable to swallow capsules or tablets or diseases significantly affecting GIfunction

13. Hypersensitivity to zanubrutinib, sonrotoclax, or any of its excipients

14. Use of investigational agents within the last 4 weeks before screening

15. Pregnant and lactating females

Note: Other protocol defined Inclusion/Exclusion criteria may apply